Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.71 |
| ▸ | MAOA | P21397 | 4/20 | 0.71 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.64 |
| ▸ | APP | P05067 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3498840 | 0.85 | NR4A2 (0.71) | MAOBMAOANR4A2APPNPC1 | |
| SCHEMBL68570 | 0.85 | ALOX5 (0.69) | MAOBNR4A2NPC1RAB9AALDH1A1 | |
| SCHEMBL2367221 | 0.84 | POLB (0.56) | MAOBMAOANPC1RAB9AALDH1A1 | |
| SCHEMBL6295262 | 0.84 | NPC1 (0.70) | MAOBMAOANR4A2APPNPC1 | |
| SCHEMBL9627289 | 0.84 | MAOB (0.68) | MAOBMAOANR4A2APPNPC1 | |
| SCHEMBL48823 | 0.84 | L3MBTL1 (0.55) | NPC1RAB9AALDH1A1MAPTPOLB | |
| SCHEMBL9778577 | 0.83 | MAOB (1.00) | MAOBMAOANR4A2NPC1RAB9A | |
| SCHEMBL27589283 | 0.83 | MAOB (0.71) | MAOBMAOANR4A2APPNPC1 | |
| SCHEMBL9632286 | 0.82 | MAOB (0.53) | MAOBMAOARAB9AALDH1A1MAPT | |
| Ethylene SCHEMBL11248134 | 0.82 | ALOX5 (0.66) | MAOBNR4A2NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152234-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2011-06-23 | — | — | US | disclosed |
| US-7956084-B2 | Phenyl thiophene carboxamide compounds as inhibitors of the enzyme IKK-2 | ASTRAZENECA AB (SE) | 2011-06-07 | — | — | US | disclosed |
| EP-1421074-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-09-29 | — | — | EP | disclosed |
| US-20070015819-A1 | Novel compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2007-01-18 | — | — | US | disclosed |
| US-7125896-B2 | Thiophene carboxamide compounds as inhibitors of enzyme IKK-2 | ASTRAZENECA AB (SE) | 2006-10-24 | — | — | US | disclosed |
| US-20040242573-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2004-12-02 | — | — | US | disclosed |
| US-4329367-A | ANTIHYPERTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1982-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015819-A1 | Novel compounds | CNR1, ABCG2, CNR2 | MAOB 577/4885MAOA 1381/4885NR4A2 814/4885 |
| US-20040242573-A1 | Novel compounds | SULT1E1, TPMT, UGT1A1 | MAOB 852/4885MAOA 1534/4885NR4A2 894/4885 |
| US-20110152234-A1 | Novel Compounds | CNR1, ABCG2, CNR2 | MAOB 577/4885MAOA 1381/4885NR4A2 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.